Publication
Finance Act 2025 receives Royal Assent
The Finance Act 2025, bringing into force measures announced in the October 30, 2024, Budget, has now come into force.
Current controversy around the waiver of intellectual property rights for COVID-19 Vaccines and implications for life sciences companies
The Life Sciences Lawyer Magazine
As the COVID pandemic lumbers on to its third year, there continues to be global disparities in access to the tools (i.e., vaccines and therapeutics) necessary to combat the pandemic.
A core reason behind this disparity is the developing world’s lack of access to the intellectual property (and technical know-how) required to manufacture these vital vaccines and therapeutics. In 2021, the United States announced that it would support the temporary waiver of intellectual property protections for COVID-19 vaccines under the Trade Related Aspects of Intellectual Property Rights (“TRIPS”) Agreement.
This article explores the current controversy around the waiver of intellectual property rights for COVID-19 vaccines and therapeutics and their implications for life sciences companies.
Read the full article from The Life Sciences Lawyer Magazine, "Current controversy around the waiver of intellectual property rights for COVID-19 Vaccines and implications for life sciences companies."
Partner-in-Charge, San Francisco
Email
jason.novak@nortonrosefulbright.com
Recent publications
Publication
HMRC publishes Pension schemes newsletter no 168
In addition to information for scheme administrators, the newsletter includes a reminder that following the abolition of the lifetime allowance from April 2024, applications for fixed protection 2016 and individual protection 2026 must be made by April 5, 2025.
Subscribe and stay up to date with the latest legal news, information and events . . .